Trial update: 2DR Versus 3DR in a Prospective Randomized Controlled Switch Trial (2DR)

Trial Update: A ViiV-partnered Ph4 study investigating the severity of HIV disease when switching to DTG/3TC from BIC/F/TAF has started recruitment, aiming to enroll 134 participants (NCT04553081). The severity of HIV will be evaluated by monitoring VL and reservoir size by measuring the amount of intact replication-competent HIV-1 sequenced in CD4 cells by intact proviral DNA assay (IPDA) as its primary endpoint (12/6).

Additional information to the following link: https://clinicaltrials.gov/ct2/history/NCT04553081?A=2&B=3&C=Side-by-Side#StudyPageTop